Clinical trials: Peptide Receptor Radionuclide Therapy (PRRT)
Neuroendocrine Tumors, Gastroenteropancreatic Neuroendocrine Tumor
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary…
- Trial name
- PRRT (NCT04090034)
- Testing
- Peptide Receptor Radionuclide Therapy
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Methodist Health System
Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3
PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)
Neuroendocrine tumours (NETs), better defined as neoplasms (NENs), are a heterogeneous group of neoplasms that range from well-differentiated tumours to more aggressive carcinomas.
- Conditions
- Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3, Neuroendocrine Gastroenteropancreatic Tumour
- Trial name
- PReCedeNT (NCT07185672)
- Testing
- Peptide Receptor Radionuclide Therapy with Lu177 DOTATATE, Capecitabine plus temozolamide
- Where
- 2 sites in India
- Volunteers
- 162 people
- Sponsor
- Tata Memorial Hospital
Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy
Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors
This is a phase 1 dose-escalation study to determine the maximum tolerated dose of the PARP inhibitor olaparib in combination with PRRT in patients with a well-differentiated advanced gastroenteropancreatic NET (GEP NET)…
- Trial name
- PRRT-PARPi (NCT05870423)
- Testing
- olaparib
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Erasmus Medical Center
Neuroendocrine Tumors
Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors
This is a randomized phase II non-comparative study. Patients with gastroenteropancreatic Neuroendocrine tumour (GEP-NET) G1-G2 with progressive disease, SSR positive and FDG negative will be enrolled in the study and will be…
- Trial name
- LUNET (NCT02489604)
- Testing
- 177Lu-DOTATATE 25.9 GBq activity, 177Lu-DOTATATE 18.5 GBq activity
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Neuroendocrine Tumors
Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients
The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive…
- Trial name
- COMPETE (NCT03049189)
- Testing
- 177Lu-edotreotide PRRT, Everolimus, Amino-Acid Solution
- Where
- 52 sites in United States, Australia and 12 more
- Volunteers
- 324 people
- Sponsor
- ITM Solucin GmbH
Pancreatic Neuroendocrine Carcinoma
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II
This study is the first randomized, open-label, national, multicenter, phase II study assessing the efficacy and safety of OCLU in subjects with pretreated progressive pancreatic, inoperable, somatostatin receptor positive, well…
- Trial name
- OCCLURANDOM (NCT02230176)
- Testing
- Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Merkel Cell Carcinoma
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
The purpose of this study is to find out what effects an immunotherapy drug, called pembrolizumab, combined with a radioactive drug, called lutetium Lu 177 dotatate (Lutathera®) have on patients with Merkel cell carcinoma.
- Trial name
- iPRRT (NCT05583708)
- Testing
- Pembrolizumab, Lutetium Lu 177 dotatate
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Weill Medical College of Cornell University
Neuroendocrine Tumors, Gastro Entero Pancreatic Neuroendocrine Tumors
Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors
The aim of this phase I-II study is to evaluate the efficacy and toxicity of PRRT with 177Lu-DOTATATE (Lu-PRRT) associated to metronomic chemotherapy with Capecitabine in patients affected by aggressive FDG-positive…
- Trial name
- LuX (NCT02736500)
- Testing
- 28 GBq 177Lu-DOTATATE, 22 GBq 177Lu-DOTATATE
- Where
- 2 sites in Italy
- Volunteers
- 39 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Thyroid Cancer, Medullary, Neuroendocrine Tumor of the Lung Grade 1 and 2
177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.
The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors.
- Conditions
- Thyroid Cancer, Medullary, Neuroendocrine Tumor of the Lung Grade 1 and 2, Neuroendocrine Tumor of the Thymus Grade 1 and 2, Neuroendocrine Tumor GEP Grade 1-3
- Trial name
- Lumed (NCT02088645)
- Testing
- 177Lu-PP-F11N
- Where
- Switzerland
- Volunteers
- 24 people
- Sponsor
- University Hospital, Basel, Switzerland
Solid Tumor
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited…
- Trial name
- LuMIERE (NCT04939610)
- Testing
- 68Ga-FAP-2286, 177Lu-FAP-2286
- Where
- 41 sites in United States, Australia and 4 more
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Meningioma
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide
Meningiomas are known to be the most frequent intracranial neoplasms and account for approx. 25-33% of all intracranial tumours.Targeted radionuclide therapy with radiolabelled somatostatin analogues, also called Peptide Receptor…
- Trial name
- PROMENADE (NCT04997317)
- Testing
- 177Lu-DOTA-JR11 (Phase 0); Cycle 1 and Cycle 2 (cross-over), 177Lu-DOTATOC (Phase 0); Cycle 1 and Cycle 2 (cross-over), Cycle 3 and 4, 177Lu-DOTA-JR11 (Phase I/II)
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- University Hospital, Basel, Switzerland
Neuroblastoma, Relapsed Neuroblastoma
67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
The aim of this study is to evaluate the safety and efficacy of 67Cu-SARTATE in pediatric patients with high-risk neuroblastoma.
- Conditions
- Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma
- Trial name
- NCT04023331
- Testing
- 67Cu-SARTATE, 64Cu-SARTATE
- Where
- 8 sites in United States
- Volunteers
- 21 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Advanced Pancreatic Cancer and Cholangiocarcinoma
A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors
This study is a prospective, single-center, open, single-arm, exploratory study to evaluate the safety and efficacy of 177Lu-EB-FAPI PRRT, and to explore 177Lu-EB-FAPI in patients with advanced pancreatic cancer and…
- Trial name
- CISPD-5 (NCT06081322)
- Testing
- PRRT with 177Lu-EB-FAPI
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Zhejiang University
Neuroendocrine Tumors
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
Neuroendocrine tumours (NETs) are slow growing cancers, which commonly present as metastatic incurable disease. Some neuroendocrine tumours, termed functional NETs, overproduce hormones which result in a variety of symptoms.
- Trial name
- STOPNET (NCT06345079)
- Testing
- Cessation of somatostatin analogues, Continuation of somatostatin analogues
- Where
- 17 sites in Australia, Canada
- Volunteers
- 78 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Gastroenteropancreatico Tumors, Neuroendocrine Tumors
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Background: A neuroendocrine tumor is a rare type of tumor. It comes from body cells called neuroendocrine cells. Sometimes, these tumors develop in the gastrointestinal tract and pancreas.
- Conditions
- Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms
- Trial name
- NCT04086485
- Testing
- Lu-177-DOTATATE, Olaparib, Ga dotatate scanning
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
This is a multicenter, open-label, single-arm study to evaluate the safety and dosimetry of Lutathera in adolescent patients 12 to <18 years old with somatostatin receptor positive GEP-NETs and PPGLs.
- Conditions
- Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
- Trial name
- NETTER-P (NCT04711135)
- Testing
- Lutetium [177Lu] oxodotreotide/dotatate
- Where
- 7 sites in United States, France and 3 more
- Volunteers
- 11 people
- Sponsor
- Advanced Accelerator Applications
Neuroendocrine (NE) Tumors
Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-[DOTA0,Tyr3]octreotate (177Lu-Dotatate) is an effective and safe treatment for patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP NET).
- Trial name
- NCT07012330
- Testing
- Capecitabine (Xeloda), 177Lu-DOTATATE
- Volunteers
- 111 people
- Sponsor
- Erasmus Medical Center
Metastatic Merkel Cell Carcinoma
Targeted Therapy and Avelumab in Merkel Cell Carcinoma
10.17 GoTHAM is intended as a signal-seeking, biomarker, phase Ib/II study that will evaluate the safety and anti-tumour activities of the novel combination of avelumab with 177-Lu-DOTATATE (a type of peptide receptor…
- Trial name
- GoTHAM (NCT04261855)
- Testing
- Avelumab, External Beam Radiation Therapy (EBRT), Lutetium-177 (177Lu)-DOTATATE
- Where
- 10 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Gastroenteropancreatic Neuroendocrine Tumor
Study of PRRT in Metastatic, WHO Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
The purpose of this study is to learn about the feasibility and safety of using Peptide Receptor Radionuclide Therapy (PRRT) before and after surgical removal of a tumor.
- Trial name
- NCT04609592
- Testing
- Lutathera, Gallium 68 Dotatate, Computed Tomography (CT)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial
According to current guidelines, patients have to withhalt long-acting somatostatin analogues (LA-SSA) for 4-6 weeks prior to every 177Lutetium-DOTATATE administration.
- Conditions
- Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Neoplasm
- Trial name
- ATSA (NCT06855095)
- Testing
- Somatostatin analog
- Where
- Netherlands
- Volunteers
- 39 people
- Sponsor
- The Netherlands Cancer Institute